Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NYXH Stock Forecast 2025-2026
$6.22
Current Price
$239.91M
Market Cap
Buy 5
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to NYXH Price Targets
+167.6%
To High Target of $16.65
+148.3%
To Median Target of $15.45
+117.0%
To Low Target of $13.50
NYXH Price Momentum
+2.0%
1 Week Change
+1.1%
1 Month Change
-24.4%
1 Year Change
-22.3%
Year-to-Date Change
-49.1%
From 52W High of $12.21
+12.1%
From 52W Low of $5.55
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Nyxoah (NYXH) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on NYXH and similar high-potential opportunities.
Latest NYXH Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, NYXH has a bullish consensus with a median price target of $15.45 (ranging from $13.50 to $16.65). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $6.22, the median forecast implies a 148.3% upside. This outlook is supported by 5 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NYXH Analyst Ratings
5
Buy
1
Hold
0
Sell
NYXH Price Target Range
Low
$13.50
Average
$15.45
High
$16.65
Current: $6.22
Latest NYXH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NYXH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 21, 2025 | Stifel | Jonathan Block | Buy | Maintains | $14.00 |
| Apr 8, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $15.00 |
| Mar 26, 2025 | HC Wainwright & Co. | Edward White | Buy | Maintains | $15.00 |
| Mar 14, 2025 | Stifel | Jonathan Block | Buy | Maintains | $15.00 |
| Dec 13, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $17.00 |
| Nov 5, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $16.00 |
| Oct 11, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $17.00 |
| Sep 30, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $18.00 |
| Aug 7, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $16.00 |
| Aug 7, 2024 | Oppenheimer | Suraj Kalia | Outperform | Maintains | $13.00 |
| Aug 7, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $18.00 |
| Jun 24, 2024 | Stifel | Jonathan Block | Buy | Maintains | $19.00 |
| May 24, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $18.00 |
| May 15, 2024 | Oppenheimer | Suraj Kalia | Outperform | Maintains | $15.00 |
| May 15, 2024 | Stifel | Jonathan Block | Buy | Maintains | $27.00 |
| May 15, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $17.00 |
| May 15, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $22.00 |
| Mar 25, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $22.00 |
| Mar 20, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $22.00 |
| Mar 20, 2024 | Stifel | Jonathan Block | Buy | Maintains | $27.00 |
Nyxoah S.A. (NYXH) Competitors
The following stocks are similar to Nyxoah based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Nyxoah S.A. (NYXH) Financial Data
Nyxoah S.A. has a market capitalization of $239.91M with a P/E ratio of -3.5x. The company generates $5.09M in trailing twelve-month revenue with a 65.7% profit margin.
Revenue growth is -30.8% quarter-over-quarter, while maintaining an operating margin of -1,449.8% and return on equity of -56.1%.
Valuation Metrics
Market Cap
$239.91M
Enterprise Value
$194.56M
P/E Ratio
-3.5x
PEG Ratio
-4.0x
Price/Sales
53.1x
Growth & Margins
Revenue Growth (YoY)
-30.8%
Gross Margin
+73.5%
Operating Margin
-1,449.8%
Net Margin
+65.7%
EPS Growth
-30.8%
Financial Health
Cash/Price Ratio
+36.7%
Current Ratio
4.6x
Debt/Equity
20.0x
ROE
-56.1%
ROA
-26.0%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Nyxoah S.A. (NYXH) Business Model
About Nyxoah S.A.
What They Do
Develops innovative solutions for sleep apnea treatment.
Business Model
Nyxoah S.A. generates revenue primarily through the sale of its Genio® system, a neurostimulation device that provides an alternative treatment for Obstructive Sleep Apnea. The company targets healthcare providers and patients, positioning its technology as a minimally invasive option compared to traditional CPAP machines, thereby tapping into a growing market of sleep disorder therapies.
Additional Information
Based in Belgium, Nyxoah is committed to enhancing patient outcomes and advancing personalized healthcare solutions in the sleep disorder sector. Its innovative approach addresses a significant need in the market, making it a potential investment opportunity within the medical technology space.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
183
CEO
Mr. Olivier Taelman
Country
Belgium
IPO Year
2021
Website
www.nyxoah.comNyxoah S.A. (NYXH) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Clover Health Investments, Corp. (CLOV) Surpasses Q1 Earnings Estimates
Clover Health Investments (CLOV) delivered earnings and revenue surprises of 171.43% and 3.06%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
May 06, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH
2 days ago
Quick Summary
Pomerantz LLP is investigating claims for investors of Nyxoah S.A. (NASDAQ: NYXH). Interested investors can contact Danielle Peyton for more information.
Why It Matters
The investigation by Pomerantz LLP may indicate potential legal issues or concerns regarding Nyxoah, which could impact its stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH
1 day ago
Quick Summary
Pomerantz LLP is investigating claims for investors of Nyxoah S.A. (NASDAQ:NYXH), signaling potential legal issues that may affect the company's stock.
Why It Matters
The investigation by Pomerantz LLP may indicate potential legal issues for Nyxoah S.A., which could affect stock performance and investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
NYXOAH SA will hold its annual and extraordinary shareholders' meetings on June 11, 2025, at 2:00 p.m. CET. Investors are invited to attend.
Why It Matters
The announcement of NYXOAH SA's shareholder meetings on June 11, 2025, signals potential corporate governance decisions and financial updates that could impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Nyxoah SA received a transparency notification from FMR LLC on May 2, 2025, in accordance with Belgian regulations on large shareholdings.
Why It Matters
The notification from FMR LLC indicates a change in shareholding, which could affect stock price and investor sentiment regarding Nyxoah's market position and stability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Nyxoah S.A. - NYXH
6 days ago
Quick Summary
Pomerantz LLP is investigating claims for Nyxoah S.A. (NASDAQ: NYXH) investors. Interested parties should contact Danielle Peyton at the provided email or phone number.
Why It Matters
The investigation by Pomerantz LLP suggests potential legal issues for Nyxoah S.A., which could impact stock performance and investor confidence, prompting scrutiny of the company's financial health.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of Nyxoah S.A. (NASDAQ:NYXH) as of April 20, 2025.
Why It Matters
The investigation into Nyxoah may indicate potential legal issues or financial concerns, which could impact stock performance and investor sentiment.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About NYXH Stock
What is Nyxoah S.A.'s (NYXH) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Nyxoah S.A. (NYXH) has a median price target of $15.45. The highest price target is $16.65 and the lowest is $13.50.
Is NYXH stock a good investment in 2025?
According to current analyst ratings, NYXH has 5 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.22. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NYXH stock?
Wall Street analysts predict NYXH stock could reach $15.45 in the next 12 months. This represents a 148.3% increase from the current price of $6.22. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Nyxoah S.A.'s business model?
Nyxoah S.A. generates revenue primarily through the sale of its Genio® system, a neurostimulation device that provides an alternative treatment for Obstructive Sleep Apnea. The company targets healthcare providers and patients, positioning its technology as a minimally invasive option compared to traditional CPAP machines, thereby tapping into a growing market of sleep disorder therapies.
What is the highest forecasted price for NYXH Nyxoah S.A.?
The highest price target for NYXH is $16.65 from at , which represents a 167.6% increase from the current price of $6.22.
What is the lowest forecasted price for NYXH Nyxoah S.A.?
The lowest price target for NYXH is $13.50 from at , which represents a 117.0% increase from the current price of $6.22.
What is the overall NYXH consensus from analysts for Nyxoah S.A.?
The overall analyst consensus for NYXH is bullish. Out of 7 Wall Street analysts, 5 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $15.45.
How accurate are NYXH stock price projections?
Stock price projections, including those for Nyxoah S.A., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2025 4:14 PM UTC